Relapsed/Refractory HER2+ Metastatic Breast Cancer

EP1: Case 1: 63-Year-Old Woman With Relapsed HER2+ Breast Cancer

March 30th 2021

The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.

EP2: Case 1: DESTINY-Breast01

March 30th 2021

Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.

EP3: Case 1: HER2CLIMB Trial

March 30th 2021

The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.

EP4: Case 1: Practical Experience With the HER2CLIMB Regimen

March 30th 2021

The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.

EP5: Case 2: Relapsed HER2+ Metastatic Breast Cancer With Stable Brain Mets

March 30th 2021

The experts present and discuss a case of a patient with relapsed HER2+ metastatic breast cancer with stable brain metastases.

EP6: Case 2: Looking at Data in Breast Cancer Patients With Brain Mets

March 30th 2021

The experts discuss data from clinical trials of metastatic breast cancer with brain involvement.

EP7: Case 2: Later-Lines of Treatment in Metastatic Breast Cancer

March 30th 2021

Key opinion leaders consider later-lines of therapy in metastatic breast cancer with lung and brain involvement.

EP8: Case 2: Clinical Experience with the Tucatinib Regimen

March 30th 2021

A panel of experts review the tucatinib regimen including adverse effects to keep an eye on.

EP9: Case 3: Relapsed HER2+ Metastatic Breast Cancer With Progressing Brain Mets

April 29th 2021

Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.

EP10: Case 3: The NALA Trial

April 29th 2021

Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.